Emerging drugs for functional dyspepsia

Bibliography

• Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005;3(6):543–52
   PubMed Web of Science ®Google Scholar
• Ford AC, Marwaha A, Sood R, et al. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130(5):1466–79
   PubMed Web of Science ®Google Scholar
• Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med 2001;134(9 Pt 2):815–22
   PubMed Web of Science ®Google Scholar
• Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130(5):1466–79
   PubMed Web of Science ®Google Scholar
• Tack J, Masaoka T, Janssen P. Functional dyspepsia. Curr Opin Gastroenterol 2011;27(6):549–76
   PubMed Web of Science ®Google Scholar
• Thumshirn M. Pathophysiology of functional dyspepsia. Gut 2002;51(Suppl 1):i63–6
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Talley NJ. Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2003;18(4):387–93
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002;50(Suppl IV):10–12
   Google Scholar
• Haycox A, Einarson T, Eggleston A. The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:38–47
   PubMedGoogle Scholar
• Lacy BE, Talley NJ, Locke GRIII, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012;36(1):3–15
   PubMed Web of Science ®Google Scholar
• Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127(4):1239–55
   PubMed Web of Science ®Google Scholar
• Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician- patient interaction. Ann Intern Med 1995;122(2):107–12
   PubMed Web of Science ®Google Scholar
• Quadri A, Vakil N. Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia. Aliment Pharmacol Ther 2003;17(6):835–40
   PubMed Web of Science ®Google Scholar
• van Kerkhoven LA, van Rossum LG, van Oijen MG, et al. Upper gastrointestinal endoscopy does not reassure patients with functional dyspepsia. Endoscopy 2006;38(9):879–85
   PubMed Web of Science ®Google Scholar
• Carvalho RV, Lorena SL, Almeida JR, et al. Food intolerance, diet composition, and eating patterns in functional dyspepsia patients. Dig Dis Sci 2010;55(1):60–5
   PubMed Web of Science ®Google Scholar
• Filipović BF, Randjelovic T, Kovacevic N, et al. Laboratory parameters and nutritional status in patients with functional dyspepsia. Eur J Intern Med 2011;22(3):300–4
   PubMed Web of Science ®Google Scholar
• Feinle-Bisset C, Azpiroz F. Dietary and lifestyle factors in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10(3):150–7
   PubMed Web of Science ®Google Scholar
• Chua AS, Bekkering M, Rovati LC, et al. Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia. Ann N Y Acad Sci 1994;713:451–3
   PubMed Web of Science ®Google Scholar
• Feinle C, Rades T, Otto B, et al. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology 2001;120(5):1100–7
   PubMed Web of Science ®Google Scholar
• Elta GH, Behler EM, Colturi TJ. Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, nonulcer dyspepsia and normal controls. Am J Gastroenterol 1990;85(10):1339–42
   PubMed Web of Science ®Google Scholar
• Mahadeva S, Yadav H, Rampal S, et al. Risk factors associated with dyspepsia in a rural Asian population and its impact on quality of life. Am J Gastroenterol 2010;105(4):904–12
   PubMed Web of Science ®Google Scholar
• Hu ML, Rayner CK, Wu KL, et al. Effect of ginger on gastric motility and symptoms of functional dyspepsia. World J Gastroenterol 2011;17(1):105–10
   PubMed Web of Science ®Google Scholar
• Talley NJ, Weaver AL, Zinsmeister AR. Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups. Am J Gastroenterol 1994;89(4):524–8
   PubMed Web of Science ®Google Scholar
• Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology 2009;137(1):94–100
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127(5):1329–37
   PubMed Web of Science ®Google Scholar
• Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007;5(2):178–85
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006(4):CD001960
   Google Scholar
• Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database of Syst Rev 2006(2):CD002096
   Google Scholar
• Gwee KA, Teng L, Wong RK, et al. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2009;21(4):417–24
   PubMedGoogle Scholar
• Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007;12(5):541–6
   PubMed Web of Science ®Google Scholar
• Zhao B, Zhao J, Cheng WF, et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta-analysis of randomized controlled studies with 12-month follow-up. J Clin Gastroenterol 2014;48(3):241–7
   PubMed Web of Science ®Google Scholar
• Lan L, Yu J, Chen YL, et al. Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol 2011;17(27):3242–7
   PubMed Web of Science ®Google Scholar
• Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10(3):168–74
   PubMed Web of Science ®Google Scholar
• Tack J, Talley NJ. Gastroduodenal disorders. Am J Gastroenterol 2010;105(4):757–63
   PubMed Web of Science ®Google Scholar
• Karamanolis G, Tack J. Promotility medications - now and in the future. Dig Dis 2006;24(3-4):297–307
   PubMed Web of Science ®Google Scholar
• Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007;22(3):304–10
   PubMed Web of Science ®Google Scholar
• Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96(3):689–96
   PubMed Web of Science ®Google Scholar
• Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995;274(22):1780–2
   PubMed Web of Science ®Google Scholar
• Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov Disord 1997;12(6):952–7
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Shelly S, Deeks JJ, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2011(2):CD001960
   Google Scholar
• Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115(6):1346–52
   PubMed Web of Science ®Google Scholar
• Mawe GM, Hoffman JM. Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013;10(8):473–86
   PubMed Web of Science ®Google Scholar
• Hoffman JM, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 2012;142(4):844–54
   PubMed Web of Science ®Google Scholar
• Corinaldesi R, Stanghellini V, Raiti C, et al. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987;28(3):300–5
   PubMed Web of Science ®Google Scholar
• Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008;103(8):1906–19
   PubMed Web of Science ®Google Scholar
• Cisapride withdrawn because of cardiac side effects. Pharm J 2000;265:152. Available from: http://www.pharmaceutical-journal.com/cisapride-withdrawn-because-of-cardiac-side-effects/20002355.article
   Google Scholar
• Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007;132(7):2287–90
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35(7):745–67
   PubMed Web of Science ®Google Scholar
• Bang CS, Kim JH, Baik GH, et al. Mosapride treatment for functional dyspepsia: a meta-analysis. J Gastroenterol Hepatol 2015;30(1):28–42
   PubMed Web of Science ®Google Scholar
• Briejer MR, Meulemans AL, Bosmans JP, et al. In vitro pharmacology of the novel enterokinetic R093877. Gastroenterology 1997;112(4):A705
   Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354–60
   PubMed Web of Science ®Google Scholar
• Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil 2014;26(8):1079–86
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39(3):239–53
   PubMed Web of Science ®Google Scholar
• Du Y, Su T, Song X, et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol 2014;48(4):328–35
   PubMed Web of Science ®Google Scholar
• Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicenter, randomized, double-blind, placebo-controlled trials. Gut 2008;57(6):740–6
   PubMed Web of Science ®Google Scholar
• Huang X, Lv B, Zhang S, et al. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol 2012;18(48):7371–7
   PubMed Web of Science ®Google Scholar
• Feighnner SD, Tan CP, McKee KK, et al. Receptor for motilin identified in the human gastrointestinal system. Science 1999;284(5423):2184–8
   PubMed Web of Science ®Google Scholar
• Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993;105(6):1886–99
   PubMed Web of Science ®Google Scholar
• Moshiree B, McDonald R, Hou W, et al. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 2010;55(3):675–83
   PubMed Web of Science ®Google Scholar
• Arts J, Caenepeel P, Verbeke K, et al. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54(4):455–60
   PubMed Web of Science ®Google Scholar
• Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88(2):203–7
   PubMed Web of Science ®Google Scholar
• Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303(1):218–25
   PubMed Web of Science ®Google Scholar
• Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14(12):1653–61
   PubMed Web of Science ®Google Scholar
• Dukes G, Barton M, Dewit O, et al. Pharmacokinetics, safety/tolerability, and effect on gastric emptying of the oral motilin receptor agonist, GSK962040, in healthy male and female volunteers. Neurogastroenterolol Motil 2009;21:84
   Google Scholar
• Takahashi N, Koba N, Yamamoto T, et al. Characterisation of a novel, potent and selective small molecule motilin receptor agonist, RQ-00201894. Gastroenterology 2010;138(5):S-713
   Google Scholar
• Gale JD, Colman PJ, Constantino K, et al. 235 PF-04548043, a novel motilin receptor agonist, increases gastric emptying in healthy volunteers and does not undergo tachyphylaxis. Gastroenterology 2009;136(5):A45
   Web of Science ®Google Scholar
• Barshop K, Kuo B. The investigational drug camicinal for the treatment of gastroparesis. Expert Opin Investig Drugs 2014;1–8
   Google Scholar
• Broad J, Goralczyk A, Mannur K, et al. Drugs acting at 5-HT4, D2, motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach. Neurogastroenterol Motil 2014;26(6):851–61
   PubMed Web of Science ®Google Scholar
• Hellström PM, Tack JF, Stephens KE, et al. A double-blind, randomized placebo- controlled phase II study of the pharmacokinetics of single doses of the motilin agonist GSK962040, in patients with type I diabetes mellitus (TIDM) and gastroparesis. Gastroenterology 2011;140(5):S-813
   Google Scholar
• Barton ME, Otiker T, Johnson LV, et al. A Randomized, double-blind, placebo- controlled Phase II study (MOT114479) to evaluate the safety and efficacy and dose response of 28 days of orally administered camicinal, a motilin receptor agonist, in diabetics with gastroparesis. Gastroenterology 2014;146(5):S-20
   Google Scholar
• Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005;54(12):1693–8
   PubMed Web of Science ®Google Scholar
• Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 2009;79(2):65–72
   PubMed Web of Science ®Google Scholar
• Lee KJ, Cha DY, Cheon SJ, et al. Plasma ghrelin levels and their relationship with gastric emptying in patients with dysmotility-like functional dyspepsia. Digestion 2009;80(1):58–63
   PubMed Web of Science ®Google Scholar
• Shinomiya T, Fukunaga M, Akamizu T, et al. Plasma acylated ghrelin levels correlate with subjective symptoms of functional dyspepsia in female patients. Scand J Gastroenterol 2005;40:648–53
   PubMed Web of Science ®Google Scholar
• Wo JM, Ejskjaer N, Hellström PM, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting - randomised clinical study subset data. Aliment Pharmacol Ther 2011;33(6):679–88
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25(2):e140–50
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Busciglio I, et al. Ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013;11(11):1453–9
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M, McCallum R, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology 2014;146(5):S158–9
   Google Scholar
• Arai M, Matsumura T, Tsuchiya N, et al. Rikkunshito improves the symptoms in patients with functional dyspepsia, accompanied by an increase in the level of plasma ghrelin. Hepatogastroenterology 2012;59(113):62–6
   PubMed Web of Science ®Google Scholar
• Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther 2000;294(1):33–7
   PubMed Web of Science ®Google Scholar
• Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24(6):540–5
   PubMed Web of Science ®Google Scholar
• Sun Y, Song G, McCallum RW. Evaluation of acotiamide for the treatment of functional dyspepsia. Expert Opin Drug Metab Toxicol 2014;10(8):1161–8
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61(6):821–8
   PubMed Web of Science ®Google Scholar
• Xiao G, Xie X, Fan J, et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis. ScientificWorldJournal 2014;2014:541950
   PubMedGoogle Scholar
• Nolan ML, Scott LJ. Acotiamide: first global approval. Drugs 2013;73(12):1377–83
   PubMed Web of Science ®Google Scholar
• Dinan TG, Mahmud N, Rathore O, et al. A double-blind placebocontrolled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia—are central serotoninergic responses enhanced? Aliment Pharmacol Ther 2001;15(10):1613–18
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Kindt S, Vos R, et al. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008;28(11-12):1326–33
   PubMed Web of Science ®Google Scholar
• Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10(11):1239–45
   PubMed Web of Science ®Google Scholar
• Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104(11):2779–87
   PubMed Web of Science ®Google Scholar
• Tack J, Van Den Elzen B, Tytgat G, et al. A placebo-controlled trial of the 5-HT agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil 2009;21(6):619–26
   PubMed Web of Science ®Google Scholar
• Jackson JL, O’Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108(1):65–72
   PubMed Web of Science ®Google Scholar
• Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005;40(11):1036–42
   PubMed Web of Science ®Google Scholar
• Locke GR, Bouras EP, Howden CW, et al. The functional dyspepsia treatment trial (FDTT) key results. Gastroenterology 2013;144(5):s-140
   Google Scholar
• Braak B, Klooker TK, Wouters MM, et al. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011;34(6):638–48
   PubMed Web of Science ®Google Scholar
• Van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008;6(7):746–52
   PubMed Web of Science ®Google Scholar
• Tan VP, Cheung TK, Wong WM, et al. Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study. World J Gastroenterol 2012;18(42):6127–33
   PubMed Web of Science ®Google Scholar
• Bennett EJ, Piesse C, Palmer K, et al. Functional gastrointestinal disorders: psychological, social, and somatic features. Gut 1998;42(3):414–20
   PubMed Web of Science ®Google Scholar
• Haug TT, Wilhelmsen I, Svebak S, et al. Psychotherapy in functional dyspepsia. J Psychosom Res 1994;38(7):735–44
   PubMed Web of Science ®Google Scholar
• Haag S, Senf W, Tagay S, et al. Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment Pharmacol Ther 2007;25(8):973–86
   PubMed Web of Science ®Google Scholar
• Hamilton J, Guthrie E, Creed F, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000;119(3):661–9
   PubMed Web of Science ®Google Scholar
• Calvert EL, Houghton LA, Cooper P, et al. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002;123(6):1778–85
   PubMed Web of Science ®Google Scholar
• Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for non-ulcer dyspepsia. Cochrane Database of Syst Rev 2005(2):CD002301
   Google Scholar
• Lahner E, Bellentani S, Bastiani RD, et al. A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders. United European Gastroenterol J 2013;1(5):385–93
   PubMed Web of Science ®Google Scholar
• Thompson Coon J, Ernst E. Systematic review: herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002;16(10):1689–99
   PubMed Web of Science ®Google Scholar
• Krueger D, Gruber L, Buhner S, et al. The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine. Neurogastroenterol Motil 2009;21(11):1203–e110
   PubMed Web of Science ®Google Scholar
• Melzer J, Rösch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004;20(11-12):1279–87
   PubMed Web of Science ®Google Scholar
• Qin F, Huang X, Ren P. Chinese herbal medicine modified xiaoyao san for functional dyspepsia: meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2009;24(8):1320–5
   PubMed Web of Science ®Google Scholar
• Xiao Y, Liu YY, Yu KQ, et al. Chinese herbal medicine liu jun zi tang and xiang sha liu jun zi tang for functional dyspepsia: meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2012;2012:936459
   PubMedGoogle Scholar
• Suzuki H, Matsuzaki J, Fukushima Y, et al. Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil 2014;26(7):950–61
   PubMed Web of Science ®Google Scholar
• Yong SK, Miwon S. DA-9701: a new multi-acting drug for the treatment of functional dyspepsia. Biomol Ther (Seoul) 2013;21(3):181–9
   PubMed Web of Science ®Google Scholar
• Xu S, Hou X, Zha H, et al. Electroacupuncture accelerates solid gastric emptying and improves dyspeptic symptoms in patients with functional dyspepsia. Dig Dis Sci 2006;51(12):2154–9
   PubMed Web of Science ®Google Scholar
• Stein DJ, Bruce Lydiard R, Herman BK, et al. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int Clin Psychopharmacol 2009;24(3):126–32
   PubMed Web of Science ®Google Scholar
• Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995;332(25):1685–90
   PubMed Web of Science ®Google Scholar
• Barber A, Bartoszyk GD, Bender HM, et al. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994;113(4):1317–27
   PubMed Web of Science ®Google Scholar
• Read NW, Abitbol JL, Bardhan KD, et al. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997;41(5):664–8
   PubMed Web of Science ®Google Scholar
• Talley NJ, Choung RS, Camilleri M, et al. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008;27(11):1122–31
   PubMed Web of Science ®Google Scholar
• Walker MM, Aggarwal KR, Shim LS, et al. Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol 2014;29(3):474–9
   PubMed Web of Science ®Google Scholar
• Hall W, Buckley M, Crotty P, et al. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol 2003;1(5):363–9
   PubMed Web of Science ®Google Scholar
• Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia. Aliment Pharmacol Ther 2010;31(11):1229–36
   PubMed Web of Science ®Google Scholar
• Friesen CA, Schurman JV, Colombo JM, et al. Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia. World J Gastrointest Pharmacol Ther 2013;4(4):86–96
   PubMedGoogle Scholar
• Friesen CA, Sandridge L, Andre L, et al. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila) 2006;45(2):143–7
   PubMed Web of Science ®Google Scholar
• Friesen CA, Kearns GL, Andre L, et al. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr 2004;38(3):343–51
   PubMed Web of Science ®Google Scholar
• Friesen CA, Neilan NA, Schurman JV, et al. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol 2009;9:32
   PubMed Web of Science ®Google Scholar